MD Anderson, Boehringer launch virtual center for data-driven drug discovery

Houston-based MD Anderson Cancer Center and international pharmaceutical company Boehringer Ingelheim have established a Virtual Research and Development Center to accelerate research into new cancer treatments.

Advertisement

The center will enable data sharing and analysis for researchers from both organizations. The initiative will be led in part by the team from MD Anderson’s Therapeutics Discovery division, which studies clinical data to understand how and for which patients new treatments will be most effective. Their findings will then be fed into Boehringer’s existing pipeline for the development of novel medicines.

Among the collaboration’s targets are treatments for mutations in the KRAS gene, commonly associated with certain types of lung and gastrointestinal cancers, and the development of an antibody with the ability to induce apoptosis.

More articles on innovation:
6 key quotes about innovation’s role in healthcare
Apple Health researcher jumps ship for Gates Foundation’s digital health group
The key to successful innovation? ‘The art of noticing’

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

What clinicians need from AI after the pilot: Lessons from Adventist Health and Rady Children’s

Friday, July 24
12:00 PM - 1:00 PM CDT

Presenters: Dr. Dieter Sumerauer, Rady Children’s HealthDr. Salman Naqvi, AdventistDr. Reid Conant, Abridge

Advertisement

Next Up in Innovation

Advertisement

Comments are closed.